文献速递呼吸危重症与机械通气

阿司匹林减轻人ARDS模型中脂多糖诱导的肺部炎症

Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS.
PubMed 文献 · Thorax · 2017-01-12

该研究在健康志愿者和离体灌注人肺模型中验证阿司匹林对ARDS相关炎症的作用。健康志愿者随机接受安慰剂或阿司匹林75mg或1200mg共7天后吸入50µg LPS,6小时后支气管肺泡灌洗。阿司匹林未降低BAL IL-8,但减少肺部中性粒细胞增多、中性粒细胞蛋白酶、TNF-α及系统与肺部TXB2,高剂量与低剂量无差异。离体肺模型亦显示阿司匹林减少BAL中性粒细胞和肺泡损伤。

要点

  • 阿司匹林未降低健康志愿者LPS吸入后BAL IL-8这一主要终点。
  • 阿司匹林减少BAL中性粒细胞、MMP-8/-9、TNF-α及TXB2。
  • 离体灌注人肺模型中阿司匹林减轻BAL中性粒细胞和肺泡损伤。

核心结论

  • 阿司匹林在低剂量和高剂量下均抑制肺部中性粒细胞炎症,为首次前瞻性人体数据。

研究设计与样本

  • 双盲、安慰剂对照、分配隐藏研究,健康志愿者随机接受安慰剂或阿司匹林75mg或1200mg(1:1:1)7天后吸入50µg LPS,6小时后行BAL,主要终点为BAL IL-8。
  • 离体灌注通气人肺模型随机接受安慰剂或24mg阿司匹林,LPS损伤后4小时行BAL评估炎症。

主要发现

  • 健康志愿者模型(n=33)中阿司匹林组数据合并分析,阿司匹林未降低BAL IL-8。
  • 阿司匹林减少肺部中性粒细胞增多和中性粒细胞蛋白酶(MMP-8/-9),降低BAL TNF-α浓度,降低系统和肺部TXB2。
  • 高剂量与低剂量阿司匹林之间无差异。
  • 离体灌注人肺模型中阿司匹林减少BAL中性粒细胞增多和组织学肺泡损伤。

关键数值与推荐

  • 健康志愿者吸入50µg LPS,6小时后行BAL,主要终点BAL IL-8。
  • 阿司匹林剂量为75mg或1200mg共7天,离体肺模型为24mg。

临床怎么用

  • 提示阿司匹林可能通过抗血小板和免疫调节作用抑制肺部中性粒细胞炎症,但尚需进一步临床研究评估其在ARDS预防和治疗中的作用。

局限性

  • 研究为人体模型(健康志愿者LPS吸入和离体灌注肺),非ARDS患者临床结局研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Platelets play an active role in the pathogenesis of acute respiratory distress syndrome (ARDS). Animal and observational studies have shown aspirin's antiplatelet and immunomodulatory effects may be beneficial in ARDS. OBJECTIVE: To test the hypothesis that aspirin reduces inflammation in clinically relevant human models that recapitulate pathophysiological mechanisms implicated in the development of ARDS. METHODS: Healthy volunteers were randomised to receive placebo or aspirin 75 or 1200 mg (1:1:1) for seven days prior to lipopolysaccharide (LPS) inhalation, in a double-blind, placebo-controlled, allocation-concealed study. Bronchoalveolar lavage (BAL) was performed 6 hours after inhaling 50 µg of LPS. The primary outcome measure was BAL IL-8. Secondary outcome measures included markers of alveolar inflammation (BAL neutrophils, cytokines, neutrophil proteases), alveolar epithelial cell injury, systemic inflammation (neutrophils and plasma C-reactive protein (CRP)) and platelet activation (thromboxane B2, TXB2). Human lungs, perfused and ventilated ex vivo (EVLP) were randomised to placebo or 24 mg aspirin and injured with LPS. BAL was carried out 4 hours later. Inflammation was assessed by BAL differential cell counts and histological changes. RESULTS: In the healthy volunteer (n=33) model, data for the aspirin groups were combined. Aspirin did not reduce BAL IL-8. However, aspirin reduced pulmonary neutrophilia and tissue damaging neutrophil proteases (Matrix Metalloproteinase (MMP)-8/-9), reduced BAL concentrations of tumour necrosis factor α and reduced systemic and pulmonary TXB2. There was no difference between high-dose and low-dose aspirin. In the EVLP model, aspirin reduced BAL neutrophilia and alveolar injury as measured by histological damage. CONCLUSIONS: These are the first prospective human data indicating that aspirin inhibits pulmonary neutrophilic inflammation, at both low and high doses. Further clinical studies are indicated to assess the role of aspirin in the prevention and treatment of ARDS. TRIAL REGISTRATION NUMBER: NCT01659307 Results.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Hamid U, Krasnodembskaya A, Fitzgerald M, et al. Aspirin reduces lipopolysaccharide-induced pulmonary inflammation in human models of ARDS. Thorax. 2017. PMID: 28082531. doi:10.1136/thoraxjnl-2016-208571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。